



OPEN ACCESS

**Edited by:**

Maria Eulalia Rubio,  
University of Pittsburgh,  
United States

**Reviewed by:**

Barbara Jane Morley,  
Boys Town National Research  
Hospital, United States  
Jerrel Yakel,  
National Institute of Environmental  
Health Sciences (NIEHS),  
United States

**\*Correspondence:**

Ana Belén Elgoyhen  
elgoyhen@dna.uba.ar

† These authors have contributed  
equally to this work and share first  
authorship

‡ These authors share senior  
authorship

**§ Present address:**

Marcelo J. Moglie,  
The Francis Crick Institute,  
London, United Kingdom  
Irina Marcovich,  
Departments of Otolaryngology &  
Neurology, Boston Children's  
Hospital, Harvard Medical School,  
Boston, MA, United States

**Received:** 09 December 2020

**Accepted:** 11 January 2021

**Published:** 05 February 2021

**Citation:**

Moglie MJ, Marcovich I, Corradi J,  
Carpaneto Freixas AE, Gallino S,  
Plazas PV, Bouzat C, Lipovsek M and  
Elgoyhen AB (2021) Loss of Choline  
Agonism in the Inner Ear Hair Cell  
Nicotinic Acetylcholine Receptor  
Linked to the  $\alpha 10$  Subunit.  
*Front. Mol. Neurosci.* 14:639720.  
doi: 10.3389/fnmol.2021.639720.

# Loss of Choline Agonism in the Inner Ear Hair Cell Nicotinic Acetylcholine Receptor Linked to the $\alpha 10$ Subunit

Marcelo J. Moglie<sup>1†§</sup>, Irina Marcovich<sup>1†§</sup>, Jeremías Corradi<sup>2</sup>, Agustín E. Carpaneto Freixas<sup>1</sup>, Sofía Gallino<sup>1</sup>, Paola V. Plazas<sup>3</sup>, Cecilia Bouzat<sup>2</sup>, Marcela Lipovsek<sup>1,4‡</sup> and Ana Belén Elgoyhen<sup>1\*§</sup>

<sup>1</sup>Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres" (INGEBI), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina, <sup>2</sup>Departamento de Biología, Bioquímica y Farmacia, Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB), Universidad Nacional del Sur y Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina, <sup>3</sup>Instituto de Farmacología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina, <sup>4</sup>Centre for Developmental Neurobiology, King's College London, Institute of Psychiatry, Psychology, and Neuroscience, Guy's Campus, London, United Kingdom

The  $\alpha 9\alpha 10$  nicotinic acetylcholine receptor (nAChR) plays a fundamental role in inner ear physiology. It mediates synaptic transmission between efferent olivocochlear fibers that descend from the brainstem and hair cells of the auditory sensory epithelium. The  $\alpha 9$  and  $\alpha 10$  subunits have undergone a distinct evolutionary history within the family of nAChRs. Predominantly in mammalian vertebrates, the  $\alpha 9\alpha 10$  receptor has accumulated changes at the protein level that may ultimately relate to the evolutionary history of the mammalian hearing organ. In the present work, we investigated the responses of  $\alpha 9\alpha 10$  nAChRs to choline, the metabolite of acetylcholine degradation at the synaptic cleft. Whereas choline is a full agonist of chicken  $\alpha 9\alpha 10$  receptors it is a partial agonist of the rat receptor. Making use of the expression of  $\alpha 9\alpha 10$  heterologous receptors, encompassing wild-type, heteromeric, homomeric, mutant, chimeric, and hybrid receptors, and *in silico* molecular docking, we establish that the mammalian (rat)  $\alpha 10$  nAChR subunit underscores the reduced efficacy of choline. Moreover, we show that whereas the complementary face of the  $\alpha 10$  subunit does not play an important role in the activation of the receptor by ACh, it is strictly required for choline responses. Thus, we propose that the evolutionary changes acquired in the mammalian  $\alpha 9\alpha 10$  nAChR resulted in the loss of choline acting as a full agonist at the efferent synapse, without affecting the triggering of ACh responses. This may have accompanied the fine-tuning of hair cell post-synaptic responses to the high-frequency activity of efferent medial olivocochlear fibers that modulate the cochlear amplifier.

**Keywords:** cochlea, nicotinic receptors, evolution, hearing, choline, acetylcholine, ion channels

## INTRODUCTION

The  $\alpha 9\alpha 10$  nicotinic acetylcholine receptor (nAChR) belongs to the pentameric family of ligand-gated ion channels (Elgoyhen et al., 1994, 2001; Sgard et al., 2002). Each subunit has a large extracellular N-terminal region, four transmembrane helices (M1–M4), and an intracellular domain. At the interface of the extracellular domains of adjacent subunits lies the orthosteric binding site, composed of a principal component or face provided by one subunit, which contributes three loops of highly conserved residues (loops A–C), and a complementary component of the adjacent subunit, which contributes three loops (loops D–F) with lower levels of sequence conservation among subunits (Thompson et al., 2010). Conserved aromatic residues present within the loops participate in cation- $\pi$  interactions with the agonists that are fundamental for triggering receptor gating (Karlin, 2002).

The  $\alpha 9\alpha 10$  receptor is an atypical member of the nAChR family. Both the  $\alpha 9$  and  $\alpha 10$  subunits have low amino acid sequence identity when compared to other member subunits (Elgoyhen et al., 1994, 2001, 2009; Franchini and Elgoyhen, 2006; Lipovsek et al., 2012, 2014; Marcovich et al., 2020) and  $\alpha 9\alpha 10$  receptors have a baroque pharmacological profile (Rothlin et al., 1999, 2003; Verbitsky et al., 2000; Ballesteros et al., 2005). Indeed, nicotine, the canonical agonist that characterizes the receptor subfamily, does not activate  $\alpha 9\alpha 10$  nAChRs but blocks ACh-gated currents (Elgoyhen et al., 1994, 2001; Sgard et al., 2002). Moreover, the  $\alpha 9\alpha 10$  nAChR has a mixed nicotinic and muscarinic profile, since it is blocked by the nicotinic antagonists curare and  $\alpha$ -bungarotoxin and the muscarinic antagonist atropine (Elgoyhen et al., 1994, 2001; Sgard et al., 2002). Also, the  $\alpha 9\alpha 10$  receptor shares pharmacological properties with type A  $\gamma$ -aminobutyric acid, glycine, and type 3 serotonin receptors, also members of the pentameric family of ligand-gated ion channels (Rothlin et al., 1999, 2003).

The atypical features of the  $\alpha 9\alpha 10$  receptor prompted the hypothesis that  $\alpha 9$  and  $\alpha 10$  subunits have undergone a distinct evolutionary history within the family of nAChRs. Using codon-based likelihood models we showed that mammalian, unlike non-mammalian,  $\alpha 10$  subunits have been under selective pressure and acquired a greater than expected number of non-synonymous amino acid substitutions in their coding region (Franchini and Elgoyhen, 2006; Elgoyhen and Franchini, 2011). Moreover, mammalian specific amino acid substitutions in the  $\alpha 9$  subunit, that show an increased posterior probability of functional divergence in this clade, are involved in the higher relative calcium permeability of mammalian  $\alpha 9\alpha 10$  receptors (Lipovsek et al., 2014; Marcovich et al., 2020). Overall, these patterns of evolutionary changes at the protein level may relate to the evolutionary history of the mammalian hearing organ (Marcovich et al., 2020), which has the highest frequency sensitivity among vertebrate auditory systems (Manley, 2000). In particular,  $\alpha 9\alpha 10$  nAChRs mediate the synapses between efferent fibers and sensory hair cells that modulate sound amplification processes, including the mammalian-exclusive prestin-driven somatic electromotility of outer hair cells (OHCs; Katz and Elgoyhen, 2014; Goutman et al., 2015). Overall, the distinct

evolutionary history of mammalian  $\alpha 9\alpha 10$  nAChRs resulted in differential calcium permeability, current-voltage relationship, and desensitization profile of  $\alpha 9\alpha 10$  receptors across vertebrate species (Lipovsek et al., 2012, 2014; Marcovich et al., 2020), together with the loss of functional homomeric  $\alpha 10$  receptors (Elgoyhen et al., 2001; Sgard et al., 2002; Lipovsek et al., 2012) and a non-equivalent contribution of different subunit interfaces to functional binding sites in mammals (Boffi et al., 2017).

One striking feature of the pharmacology of mammalian  $\alpha 9\alpha 10$  receptors, compared to other nAChRs, is the scarcity of identified compounds capable of behaving as agonists of the receptor since most typical nicotinic agonists block rat  $\alpha 9\alpha 10$  nAChRs (Verbitsky et al., 2000; Elgoyhen et al., 2001). Whether these observations are related to the peculiar evolutionary history of the mammalian receptor and do not, therefore, extend to other non-mammalian  $\alpha 9\alpha 10$  nAChRs, is still an open question. In the present work we have addressed this by comparing the effects of classical nicotinic agonists: nicotine, carbachol, DMPP, and choline, on rat and chicken  $\alpha 9\alpha 10$  nAChRs. We report that, as for rat receptors, nicotine does not activate but blocks chicken  $\alpha 9\alpha 10$  nAChRs. However, whereas choline is a partial agonist of rat  $\alpha 9\alpha 10$  receptors, it is a full agonist of chicken  $\alpha 9\alpha 10$  receptors. Similarly, DMPP has a higher efficacy in chicken receptors. Using hybrid and chimeric receptors we show that the lower agonistic efficacy of choline in rat  $\alpha 9\alpha 10$  receptors is linked to the extracellular region of the mammalian  $\alpha 10$  subunit. Most importantly, we describe that complementary components of the ligand-binding site provided by the rat  $\alpha 10$  subunit non-equivalently contribute to receptor activation by ACh and choline. Thus, whereas ACh does not utilize interfaces where  $\alpha 10$  provides the complementary component to elicit maximal responses, choline requires fully competent  $\alpha 10$  interfaces for receptor activation, suggesting a requirement for a higher degree of ligand occupancy when choline is the agonist. In line with these results, molecular docking simulations indicate that choline binds at all interfaces with a different orientation concerning that of ACh, and it does so with different frequencies depending on which subunit contributes the complementary side. Overall, we propose that the loss of choline full agonism in mammalian  $\alpha 9\alpha 10$  receptors was driven by changes in the  $\alpha 10$  subunit. This may have resulted from functional selection pressure on the fine-tuning of cholinergic responses within the mammalian efferent synapse.

## MATERIALS AND METHODS

### Expression of Recombinant Receptors in *X. laevis* Oocytes

For expression studies, rat and chicken  $\alpha 9$  and  $\alpha 10$  nAChR subunits subcloned into a modified pGEMHE vector were used. Capped cRNAs were *in vitro* transcribed from linearized plasmid DNA templates using RiboMAX<sup>TM</sup> Large Scale RNA Production System (Promega, Madison, WI, USA). The maintenance of *X. laevis* and the preparation and cRNA injection of stage V and VI oocytes have been described in detail elsewhere (Verbitsky et al., 2000). Typically, oocytes

were injected with 50 nl of RNase-free water containing 0.01–1.0 ng of cRNA (at a 1:1 molar ratio for heteromeric receptors) and maintained in Barth's solution [in mM: NaCl 88, Ca(NO<sub>3</sub>)<sub>2</sub> 0.33, CaCl<sub>2</sub> 0.41, KCl 1, MgSO<sub>4</sub> 0.82, NaHCO<sub>3</sub> 2.4, HEPES 10] at 18°C. Electrophysiological recordings were performed 2–6 days after cRNA injection under a two-electrode voltage clamp with an Oocyte Clamp OC-725B or C amplifier (Warner Instruments Corporation, Hamden, CT, USA). Recordings were filtered at a corner frequency of 10 Hz using a 900 BT Tunable Active Filter (Frequency Devices Inc., Ottawa, IL, USA). Data acquisition was performed using a Patch Panel PP-50 LAB/1 interphase (Warner Instruments Corp., Hamden, CT, USA) at a rate of 10 points per second. Both voltage and current electrodes were filled with 3 M KCl and had resistances of ~1 M $\Omega$ . Data were analyzed using Clampfit from the pClamp 6.1 software. During electrophysiological recordings, oocytes were continuously superfused (~15 ml/min) with normal frog saline composed of: 115 mM NaCl, 2.5 mM KCl, 1.8 mM CaCl<sub>2</sub>, and 10 mM HEPES buffer, pH 7.2. Drugs were added to the perfusion solution for the application. The membrane potential was clamped to -70 mV. To minimize activation of the endogenous Ca<sup>2+</sup> sensitive chloride current (Elgoyhen et al., 2001), all experiments were performed in oocytes incubated with the Ca<sup>2+</sup> chelator 1,2-bis (2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid-acetoxymethyl ester (BAPTA-AM, 100  $\mu$ M) for 3 h before electrophysiological recordings. Concentration-response curves were normalized to the maximal ACh response in each oocyte. For the inhibition curves, nicotine was added to the perfusion solution for 2 min before the addition of 10  $\mu$ M ACh and then coapplied with this agonist, and responses were referred to as a percentage of the response to ACh. The mean and SEM of peak current responses are presented. Agonist concentration-response curves were iteratively fitted, using Prism 6 software (GraphPad Software Inc., La Jolla, CA, USA), with the equation:  $I/I_{\max} = A^{nH}/(A^{nH} + EC_{50}^{nH})$ , where  $I$  is the peak inward current evoked by agonist at concentration  $A$ ;  $I_{\max}$  is the current evoked by the concentration of agonist eliciting a maximal response;  $EC_{50}$  is the concentration of agonist inducing half-maximal current response, and  $nH$  is the Hill coefficient. An equation of the same form was used to analyze the concentration dependence of antagonist induced blockage. The parameters derived were the concentration of antagonist producing a 50% block of the control response to ACh ( $IC_{50}$ ) and the associated interaction coefficient ( $nH$ ).

The  $\alpha 10W55T$  mutant subunit was produced as previously described (Boffi et al., 2017) using Quick change XL II kit (Stratagene, La Jolla, CA, USA). The chimeric  $\alpha 10_x$  construct was generated in two steps. First, the DNA fragment encoding the  $\alpha 10$  N-terminal domain was replaced by the DNA sequence encoding the  $\alpha 9$  N-terminal domain, by overlap-extension PCR (Horton et al., 1989). Briefly, the DNA sequence of the  $\alpha 9$  N-terminal domain was amplified from an  $\alpha 9$  pGEMHE construct using primers 5'-GGGCGAATTAATTTCGAGCTC-3' and 5'-CACCTTCACTCTCCTTCTGAAGCGCCGCGCTGCAGCCTACGTGTG-3', and the DNA sequence of the

$\alpha 10$  subunit from TM1 to the C-terminal domain was amplified from an  $\alpha 10$  pSGEM construct using primers 5'-CACACGTAGGCTGCAGCGCGGCGCTTCAGAAGGAGAGTGAAGGTG-3' and 5'-GCTATGACCATGATTACGCC-3'. The chimeric subunit was amplified using the DNA fragments generated in the two PCRs described above and primers 5'-GGGCGAATTAATTTCGAGCTC-3' and 5'-GCTATGACCATGATTACGCC-3', and subcloned in pSGEM vector. In a second step, conversion of both the pre TM1 and the TM2-TM3 loop from the chimera to the corresponding  $\alpha 9$  sequence was performed by QuikChange Multi Site-Directed Mutagenesis kit (Stratagene) using primers 5'-GGCATGCTCTCGGCCACCATCAGCTGGAAGACGG-3' and 5'-GGGCAGCAGGAGGTTGACGATGTAGAATGAAGAGCGGCGCTTCAG-3'. All mutant and chimeric subunits were confirmed by sequencing.

## Recordings From Hair Cells

Chicken auditory organ (basilar papilla) was dissected from the temporal bone of embryonic chickens (white Leghorns either sex, 17–20 days *in ovo*). The tegmentum vasculosum was removed and the tectorial membrane was stripped from the basilar papilla with most of the short hair cells (SHCs) still attached. This “tectorial preparation” was then inverted and secured in the recording chamber by spring clips. SHCs were recorded in a region 25–50% the distance from the apical (lagenar) to the basal tip of the basilar papilla of the chicken. Apical turns of the organ of Corti were excised from BALB/c mice of either sex between postnatal day 11 (P11) and P13 (around the onset of hearing in altricial rodents). At this age, outer hair cells (OHCs) are already innervated by the MOC fibers (Pujol et al., 1998; Simmons, 2002). The tectorial membrane was removed and the organ of Corti was positioned under an insect pin affixed to a cover-slip with a drop of Sylgard.

Basilar papilla and cochlear preparations were placed into a chamber on the stage of an upright microscope (Olympus BX51WI, Center Valley, PA, USA) at room temperature and used within 2 h. Cells were visualized on a monitor *via* a water immersion objective (60 $\times$  magnification), differential interference contrast optics, and a CCD camera (Andor iXon 885, Belfast, UK). The preparation was superfused continuously at 2–3 ml per min with an extracellular saline solution of an ionic composition similar to that of the perilymph: 144 mM NaCl, 5.8 mM KCl, 1.3 mM CaCl<sub>2</sub>, 0.9 mM MgCl<sub>2</sub>, 0.7 mM NaH<sub>2</sub>PO<sub>4</sub>, 5.6 mM D-glucose and 10 mM HEPES buffer (pH 7.4). Solutions containing ACh or choline were prepared in this same saline and delivered by a gravity-fed multichannel glass pipette (150- $\mu$ m tip diameter).

Whole-cell, tight-seal voltage-clamp recordings were made with 1 mm borosilicate glass micropipettes (WPI, Sarasota, FL, USA) ranging from 6 to 8 M $\Omega$  tip resistance. Series resistance errors were not compensated for. The recording pipette contained the following (in mM): 140 KCl, 3.5 MgCl<sub>2</sub>, 2 CaCl<sub>2</sub>, 5 EGTA, 5 HEPES, 5 mM phosphocreatine-Na<sub>2</sub> and 2.5 Na<sub>2</sub>ATP, titrated to pH 7.2 with KOH. Osmolarity was adjusted to 295 mOsm. All recordings were performed at room temperature (22–25°C).

Electrophysiological recordings were performed using a Multiclamp 700B amplifier (Molecular Devices, San Jose, CA, USA), low-pass-filtered at 2–10 kHz, and digitized at 50 kHz via a National Instruments board. Data were acquired using WinWCP (J. Dempster, University of Strathclyde, Glasgow, Scotland). Recordings were analyzed with custom-written routines in IgorPro 6.37 (Wavemetrics, Lake Oswego, OR, USA).

## Molecular Modeling and Docking

Homology models of the extracellular domain of the chick and rat  $\alpha 9\alpha 10$  nAChRs were as in Boffi et al. (2017). They were created with SWISS-MODEL (Schwede et al., 2003; Arnold et al., 2006; Bordoli et al., 2009) using the monomeric structure of the human  $\alpha 9$  subunit as the template (Protein Data Bank ID 4UY2; Zouridakis et al., 2014). The monomeric models of these proteins were then structurally aligned to the pentameric structure of *Lymnaea stagnalis* ACh binding protein (AChBP) bound to ACh (Protein Data Bank ID 3WIP; Olsen et al., 2014) using the program STAMP (Russell and Barton, 1992) from visual molecular dynamics (Humphrey et al., 1996) to obtain pentameric models with an  $(\alpha 9)_2(\alpha 10)_3$  stoichiometry bound to ACh. Four different types of possible binding site interfaces were included:  $\alpha 9/\alpha 9$ ,  $\alpha 9/\alpha 10$ ,  $\alpha 10/\alpha 9$ , and  $\alpha 10/\alpha 10$ . For each interface, the first subunit provides the principal face and the second provides the complementary face. The models were energy minimized to relax steric clashes using spdbviewer (Guex and Peitsch, 1997), and were used for docking studies after deletion of ACh from the models. Using Autodock 4.2 (Morris et al., 2009) choline and ACh were downloaded from PubChem and docked into each of the four types of interfaces for rat and chicken subunits. One-hundred genetic algorithm runs were performed for each condition. Residues R57, R111, and R117 were set as flexible to avoid steric and/or electrostatic effects that may impair agonist docking into the binding site (Boffi et al., 2017). Clustering of the results was done with Autodock based on a root-mean-square deviation cutoff of 2.0 Å. Docking results were corroborated in three different procedures. The most representative docking result was plotted with Discovery Studio Visualizer 4.5 (Dassault Systèmes BIOVIA, San Diego, CA, USA, 2016).

## Statistical Analysis

Statistical analysis was performed using the software Infostat (Universidad Nacional de Córdoba). The non-parametric Mann–Whitney test was used to perform comparisons between two groups and Kruskal–Wallis one-way analysis of variance followed by Conover's test for comparisons between multiple groups. Friedman's test was used for comparisons between paired samples. Differences between samples were considered significant when  $p < 0.05$ . All raw data and analysis code are available upon request.

## Materials

All drugs were obtained from Sigma–Aldrich (St. Louis, MO, USA). ACh, choline, DMPP, carbachol, and nicotine were dissolved in distilled water as stocks and stored aliquoted at  $-20^{\circ}\text{C}$ . BAPTA-AM was stored at  $-20^{\circ}\text{C}$  as aliquots of a

100 mM solution in dimethyl sulfoxide (DMSO), thawed and diluted 1,000-fold into Barth's solution shortly before incubation of the oocytes.

All experimental protocols were carried out following the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23) revised 1978 and INGEBI Institutional Animal Care and Use Committee.


## RESULTS

### Cholinergic Agonists Show Lower Efficacy on Rat $\alpha 9\alpha 10$ Receptors

The unique pharmacological profile of mammalian  $\alpha 9\alpha 10$  receptors (Rothlin et al., 1999, 2003; Verbitsky et al., 2000), and the observation that mammalian  $\alpha 10$  subunits have been under selection pressure (Franchini and Elgoyhen, 2006; Elgoyhen and Franchini, 2011), prompted us to examine whether this baroque pharmacology is recapitulated in receptors from a non-mammalian species. Nicotine, the prototypic agonist of nAChRs, is an antagonist of mammalian  $\alpha 9\alpha 10$  receptors (Elgoyhen et al., 1994, 2001; Sgard et al., 2002), and did not elicit currents in oocytes expressing either rat or chicken  $\alpha 9\alpha 10$  receptors. Instead, nicotine acted as an antagonist of both receptors (Figure 1A, Table 1; Elgoyhen et al., 2001), blocking responses to 10  $\mu\text{M}$  ACh in a concentration-dependent manner (rat  $\text{IC}_{50} = 46.3 \pm 12.4 \mu\text{M}$ ;  $n = 6$ ; chicken  $\text{IC}_{50} = 39.4 \pm 3.4 \mu\text{M}$ ;  $n = 6$ ;  $p = 0.81$ , Mann–Whitney test).

Next, we analyzed the effect of different nAChR agonists on  $\alpha 9\alpha 10$  receptors from the two studied species. Previous work showed that ACh elicits maximal responses in both rat and chicken  $\alpha 9\alpha 10$  receptors, with similar near 10  $\mu\text{M}$   $\text{EC}_{50}$  values (Elgoyhen et al., 2001; Lipovsek et al., 2012). The cholinergic agonist carbachol elicited concentration-dependent responses in oocytes expressing  $\alpha 9\alpha 10$  receptors (Figure 1B and Table 1) with maximal responses that were  $75 \pm 5\%$  (rat,  $n = 5$ ) and  $89 \pm 7\%$  (chicken,  $n = 6$ ) of the maximum response elicited by 1 mM ACh ( $p = 0.93$ , Mann–Whitney test).  $\text{EC}_{50}$  values for carbachol were similar for the receptors from both species:  $159 \pm 31.5 \mu\text{M}$  (rat;  $n = 5$ ),  $150 \pm 15 \mu\text{M}$  (chicken;  $n = 6$ );  $p = 0.42$ , Mann–Whitney test. The potency of carbachol was therefore nearly 12 times lower compared to that of ACh both in rat and chicken  $\alpha 9\alpha 10$  recombinant receptors (Elgoyhen et al., 2001; Lipovsek et al., 2012). As previously reported (Elgoyhen et al., 2001), the nicotinic agonist DMPP behaved as a very weak partial agonist of rat  $\alpha 9\alpha 10$  nAChRs (Figure 1C and Table 1), with a maximal response that was  $0.6 \pm 0.3\%$  ( $n = 6$ ) of that observed with 1 mM ACh ( $n = 6$ ). Surprisingly, the efficacy of DMPP on chicken  $\alpha 9\alpha 10$  receptors was significantly higher ( $p = 0.004$ , Mann–Whitney test compared to rat), reaching  $32.6 \pm 2.9\%$  of that of ACh with an  $\text{EC}_{50}$  of  $9.8 \pm 0.5 \mu\text{M}$  ( $n = 5$ ;  $p = 0.03$ , Mann–Whitney test, chick vs. rat). Finally, choline behaved as a partial agonist on rat heteromeric  $\alpha 9\alpha 10$  receptors (Figure 1D and Table 1), with a maximal response that was  $37 \pm 3\%$  of that produced by 1 mM ACh and an  $\text{EC}_{50}$  of  $541 \pm 62 \mu\text{M}$  ( $n = 10$ ). As observed for DMPP, the efficacy





**TABLE 1 |** Estimated values of  $EC_{50}$  and efficacy for agonists of  $\alpha 9\alpha 10$  receptors and  $IC_{50}$  value for the antagonist nicotine.

	ACh		Choline		Carbachol		DMPP		Nicotine
	$EC_{50}$ ( $\mu\text{M}$ )	$EC_{50}$ ( $\mu\text{M}$ )	Efficacy (%)	$EC_{50}$ ( $\mu\text{M}$ )	Efficacy (%)	$EC_{50}$ ( $\mu\text{M}$ )	Efficacy (%)	$IC_{50}$ ( $\mu\text{M}$ )	
Rat $\alpha 9$	12.9 $\pm$ 1.1 (5)	188 $\pm$ 40 (3)	87.3 $\pm$ 6.0 (4)	N.D.	N.D.	N.D.	N.D.	N.D.	
Rat $\alpha 9\alpha 10$	17.1 $\pm$ 3.1 (5)	541 $\pm$ 62 (10)	37.5 $\pm$ 2.5 (9)	159 $\pm$ 31.5 (5)	75.5 $\pm$ 5.2 (5)	21.5 $\pm$ 4.0 (6)	0.6 $\pm$ 0.3 (6)	46.3 $\pm$ 12.4 (6)	
Chicken $\alpha 9$	12.9 $\pm$ 1.4 (5)	280 $\pm$ 20 (6)	73.7 $\pm$ 5.9 (6)	N.D.	N.D.	N.D.	N.D.	N.D.	
Chicken $\alpha 10$	2.2 $\pm$ 0.7 (5)	23.2 $\pm$ 8.3 (4)	99.4 $\pm$ 9.5 (4)	N.D.	N.D.	N.D.	N.D.	N.D.	
Chicken $\alpha 9\alpha 10$	13.1 $\pm$ 2.6 (10)	200 $\pm$ 16 (6)	88.0 $\pm$ 6.7 (6)	150 $\pm$ 15 (6)	89.8 $\pm$ 7.0 (6)	9.8 $\pm$ 0.5 (5)	32.6 $\pm$ 2.9 (5)	39.4 $\pm$ 3.4 (6)	
R $\alpha 9$ -C $\alpha 10$	11.6 $\pm$ 2.9 (7)	148 $\pm$ 12.1 (5)	86.4 $\pm$ 2.1 (6)	N.D.	N.D.	N.D.	N.D.	N.D.	
C $\alpha 9$ -R $\alpha 10$	18.2 $\pm$ 4.8 (4)	333 $\pm$ 66.2 (4)	51.2 $\pm$ 6 (5)	N.D.	N.D.	N.D.	N.D.	N.D.	
$\alpha 9\alpha 10\text{x}$	15.6 $\pm$ 6.5 (4)	160.2 $\pm$ 7.6 (5)	74.3 $\pm$ 1.0 (5)	N.D.	N.D.	N.D.	N.D.	N.D.	
R $\alpha 9$ -R $\alpha 10$ W55T	37.8 $\pm$ 6.2 (8)	N.D.	7.4 $\pm$ 1.9 (5)	N.D.	N.D.	N.D.	N.D.	N.D.	


Values are mean  $\pm$  SEM. Between brackets, number of oocytes per experiment. R, rat. C, chicken. N.D., not determined.

of choline on chicken  $\alpha 9\alpha 10$  receptors was higher than that observed for rat receptors ( $n = 6$ ;  $p = 0.0004$ , Kruskal–Wallis test), reaching a maximum response of  $88 \pm 7\%$  of the maximum response to 1 mM ACh, thus behaving nearly as a full agonist. Additionally, the  $EC_{50}$  of  $200 \pm 16 \mu\text{M}$  ( $n = 6$ ) for choline in chicken  $\alpha 9\alpha 10$  receptors was nearly three times lower than that observed for rat receptors [ $EC_{50} = 541 \pm 62$  ( $n = 10$ ),  $p = 0.0025$ , Kruskal–Wallis test]. In summary, while inhibition by nicotine and agonism by carbachol was similar between chicken and rat receptors, choline and DMPP presented higher efficacies for the avian than for the mammalian  $\alpha 9\alpha 10$  heteromeric nAChRs.

## Choline Elicits Near-Maximal Responses in Chicken, but Not in Mouse, Hair Cells

Choline is naturally present at cholinergic synapses as a degradation product of ACh (Wehrwein et al., 2016) and its effect on nAChRs can have important implications for synaptic

function (Albuquerque et al., 1998). The synapse between efferent fibers and hair cells is mediated by  $\alpha 9\alpha 10$  nicotinic receptors coupled to the activation of SK2 calcium-dependent potassium channels, resulting in an inhibitory response (Fuchs and Murrow, 1992; Dulon and Lenoir, 1996; Katz et al., 2004; Gomez-Casati et al., 2005; Elgoyhen and Katz, 2012). We analyzed the effect of choline in mouse and chicken hair cells in acute explants, in comparison to ACh responses. **Figure 2A** shows representative responses to both ACh and choline at a holding potential of  $-40$  mV. These responses were outward, resulting from the activation of SK2 potassium channels coupled to the cholinergic responses. For both chicken and mouse hair cells, we observed maximal responses to 3 mM ACh. However, and in agreement with that observed for recombinant  $\alpha 9\alpha 10$  receptors, choline exhibited higher efficacy in chicken hair cells ( $90 \pm 6\%$ ,  $n = 3$ ) when compared to that on mouse hair cells ( $50 \pm 9\%$ ,  $n = 6$ ;  $p = 0.024$ , Mann–Whitney test). These observations suggest that




the differences in agonistic behavior identified in recombinant  $\alpha 9\alpha 10$  receptors are recapitulated by the native receptors present in chicken and mouse hair cells.

### The $\alpha 10$ Subunit Determines Choline Potency and Efficacy in $\alpha 9\alpha 10$ nAChRs

To determine if the agonistic characteristics of choline could be traced back to the constituent subunits of the  $\alpha 9\alpha 10$  heteromeric receptors, we first tested the potency of choline on homomeric  $\alpha 9$  and  $\alpha 10$  nAChRs. Of note, mammalian  $\alpha 10$  receptors do not assemble into functional homomeric receptors (Elgoyhen et al., 2001; Sgard et al., 2002) and were therefore not tested.

In contrast to that observed for rat heteromeric  $\alpha 9\alpha 10$  receptors (Figure 1D), choline behaved as a nearly full agonist of rat  $\alpha 9$  receptors (Figure 3A and Table 1).

Thus, although less potent than ACh ( $EC_{50}$  choline  $188 \pm 40$ ,  $n = 3$ ; ACh  $12.9 \pm 1.1$ ,  $n = 5$ ;  $p = 0.04$ , Mann-Whitney test), the maximal choline response was  $87 \pm 6\%$  ( $n = 4$ ,  $p = 0.002$ , Kruskal-Wallis test) of that elicited by 1 mM ACh. Additionally, the  $EC_{50}$  for choline observed for the rat  $\alpha 9$  receptor was smaller than that of the rat  $\alpha 9\alpha 10$  receptor (Figure 1D,  $p = 0.02$ , Kruskal-Wallis test). It is worth noting that choline was previously shown to be nearly a full agonist of rat  $\alpha 9$  homomeric receptors, albeit with a higher potency than that observed here (Verbitsky et al., 2000). Differences might derive from the fact that experiments in the present work were performed in the presence of BAPTA-AM to isolate the cholinergic responses from the secondary activation of the  $Ca^{2+}$  sensitive chloride current present in oocytes (Miledi and Parker, 1984), while this was not the case in the previous work (Verbitsky et al., 2000).



Choline had high efficacy in both chicken  $\alpha 9$  and  $\alpha 10$  homomeric receptors, similar to that observed for the chicken  $\alpha 9\alpha 10$  heteromeric receptor (Table 1). The maximal choline response in chicken  $\alpha 9$  receptors was  $73.7 \pm 5.9\%$  ( $n = 6$ ) of that obtained for 1 mM ACh (Figure 3B), and it matched the maximal ACh response in chicken  $\alpha 10$  receptors [ $99.4 \pm 9.5\%$  ( $n = 4$ ); Figure 3C]. Choline potency was lower compared to that of ACh for both chicken homomeric receptors and concentration-response curves to choline were shifted to the right with higher  $EC_{50}$  values (Figures 3B,C). For chicken  $\alpha 9$ , choline showed an  $EC_{50} = 280 \pm 20 \mu M$  ( $n = 6$ ) compared to  $12.9 \pm 1.4 \mu M$  for ACh ( $n = 5$ ,  $p = 0.004$ , Mann-Whitney test). In chicken  $\alpha 10$  receptors the  $EC_{50}$  for choline was  $23.2 \pm 8.3 \mu M$  ( $n = 4$ ), compared to  $2.2 \pm 0.7 \mu M$  for ACh ( $n = 5$ ,  $p = 0.016$ , Mann-Whitney test).

In summary, choline behaved as an agonist with high efficacy for homomeric receptors composed of rat  $\alpha 9$ , chicken  $\alpha 9$ , or chicken  $\alpha 10$  subunits. This agonistic behavior was similar to that observed for chicken  $\alpha 9\alpha 10$  receptors but differed from that of rat  $\alpha 9\alpha 10$  heteromeric receptors.


The observation that choline behaved as a partial agonist of heteromeric rat  $\alpha 9\alpha 10$  receptors, but a full agonist of rat  $\alpha 9$  homomeric nAChRs, suggests that the rat  $\alpha 10$  subunit may contain determinants responsible for the lower efficacy of choline on heteromeric  $\alpha 9\alpha 10$  receptors. To test this hypothesis, we expressed rat-chicken hybrid receptors in *X. laevis* oocytes (Figure 4). We previously determined that responses in these hybrid  $\alpha 9\alpha 10$  receptors are indeed the result of heteromeric assemblies and not individual homomeric receptors (Lipovsek et al., 2014). As shown in Figure 4A, rat  $\alpha 9$ –chicken  $\alpha 10$  hybrid receptors responded to ACh with an  $EC_{50}$  of  $11.6 \pm 2.9 \mu M$  ( $n = 7$ ), similar to that of rat ( $EC_{50}$   $17.1 \pm 3.1 \mu M$ ,  $n = 5$ ,  $p = 0.19$ , Kruskal-Wallis test) and chicken ( $EC_{50}$


$13.1 \pm 2.6 \mu M$ ,  $n = 10$ ,  $p = 0.67$ , Kruskal-Wallis test)  $\alpha 9\alpha 10$  nAChRs (Table 1). Distinct from that described for rat  $\alpha 9\alpha 10$  receptors (Figure 1D), choline produced near-maximal responses in rat  $\alpha 9$ –chicken  $\alpha 10$  hybrid receptors ( $86 \pm 2\%$  of responses to 1 mM ACh,  $n = 6$ ), that were similar to those observed in chicken  $\alpha 9\alpha 10$  receptors ( $88 \pm 7\%$ ,  $n = 6$ ). On the other hand, hybrid chicken  $\alpha 9$ –rat  $\alpha 10$  receptors exhibited similar concentration-response curves to ACh when compared to rat and chicken  $\alpha 9\alpha 10$  receptors, with an  $EC_{50}$  of  $18.2 \pm 4.8 \mu M$  ( $n = 4$ ,  $p = 0.99$ , and  $p = 0.29$ , respectively, Kruskal-Wallis test; Figure 4B and Table 1). However, the maximal response to choline of chicken  $\alpha 9$ –rat  $\alpha 10$  hybrid receptors ( $51 \pm 6\%$ ,  $n = 5$ ) was smaller than that observed for chicken  $\alpha 9\alpha 10$  receptors ( $88 \pm 7\%$ ,  $n = 10$ ,  $p = 0.02$ , Kruskal-Wallis test; Figure 1C), with lower efficacy, similar to that of rat  $\alpha 9\alpha 10$  receptors ( $37.5 \pm 2.5\%$ ,  $n = 9$ ,  $p = 0.50$ , Kruskal-Wallis test).

In summary, both the potency and efficacy of choline were lowest for rat heteromeric  $\alpha 9\alpha 10$  receptors than all other receptors, except for heteromeric hybrid receptors containing rat  $\alpha 10$  subunits, therefore suggesting that the rat  $\alpha 10$  subunit may hold the molecular determinants of choline's partial agonism (Figure 4C).

## Lower Frequency of Choline-Binding at Orthosteric Sites Holding Rat $\alpha 10$ Subunits as Complementary Components

To gain further insight into the mechanism underlying the drop in choline agonism on receptors containing the rat  $\alpha 10$  subunit, we performed molecular docking simulations and analyzed the interaction of ACh and choline with the orthosteric binding site. To this end, we used homology models of the





extracellular domains of rat and chicken  $\alpha 9\alpha 10$  receptors with subunit arrangements corresponding to the four possible binding site interfaces (principal/complementary components):  $\alpha 9/\alpha 9$ ,  $\alpha 9/\alpha 10$ ,  $\alpha 10/\alpha 9$ , and  $\alpha 10/\alpha 10$  as previously reported (Boffi et al., 2017). We then performed molecular docking analysis of the interaction of ACh or choline with the homology-modeled

subunit interfaces to evaluate the orientation, the best binding energy (BBE), and the frequency of conformations that bind the agonist in a favorable orientation within the binding pocket. The conformations considered as favorable were those that showed typical cation- $\pi$  interactions between the amino group of the ligands and aromatic residues of the binding pocket (W55, from the complementary face, and Y93, W149, Y190, and/or Y197 from the principal face) required for ACh responses (Dougherty, 2007; Olsen et al., 2014).

As reported previously (Boffi et al., 2017), both for rat and chicken receptors, ACh docking resulted in an energetically favorable model with ACh oriented with its quaternary amine toward the membrane side or lower part of the cleft and the negative charge oriented upwards in the cleft (Figures 5A,B), similar to ACh in AChBP (Olsen et al., 2014). In this orientation, ACh showed BBE between  $-3.5$  and  $-6$  kcal/mol for the different binding interfaces (Figure 5E) and its positively charged group showed the potential to form the typical cation- $\pi$  interactions with the main aromatic residues Y93, W149, Y190, Y197, and W55 (Figures 5B,C). Thus, as reported for other nAChRs, the orientation of ACh in the binding pocket of rat and chicken  $\alpha 9\alpha 10$  receptors is favorable for efficacious activation (Figure 5 and Boffi et al., 2017).

For all interfaces, choline docked into the orthosteric binding site with two different orientations. The least frequent orientation was similar to that described for choline docked into the muscle nAChR (Bruhova and Auerbach, 2017). In the most frequent and lowest BBE conformation, choline was located more horizontally with respect to the membrane compared to ACh, oriented towards the C-loop containing Y190 and Y197, with the quaternary ammonium placed in the aromatic cavity (Figures 5B,D). This orientation has also been described for other ligands in different nAChR models (Tomaselli et al., 1991; Lester et al., 2004; Hernando et al., 2012). In this orientation, choline showed the potential to make typical cation- $\pi$  interactions with the aromatic residues at the principal (W149, Y93, Y190, and Y197) and complementary (W55) components (Figure 5D). Whereas ACh formed an H-bond with the backbone amine group of residue D119 (Boffi et al., 2017 and Figures 5B,C), choline formed an H-bond with the carboxyl group of D119 (Figures 5B,D). Altogether, the orientation and potential interactions with residues indicate that choline adopts a favorable conformation (though different to that of ACh) for eliciting receptor activation, with lower BBEs than those observed for ACh (between  $-4$  and  $-4.5$  kcal/mol for all interfaces).

The orientation and main interactions of choline with residues at the binding site were identical for all interfaces and between chicken and rat receptors. Also, while the BBE for choline did not show significant inter-species differences across the alternate interfaces, we observed variations in the frequency at which choline bound with favorable conformations to the different interfaces (Figure 5E). Those binding interfaces containing  $\alpha 9$  as the complementary subunit ( $\alpha 9/\alpha 9$  and  $\alpha 10/\alpha 9$ ) showed a high frequency of choline-binding in the favorable conformations both for chicken and rat subunits (Figure 5E). In contrast, differences were encountered at interfaces in which  $\alpha 10$  provided the complementary



side ( $\alpha 9/\alpha 10$  and  $\alpha 10/\alpha 10$ ). While each agonist binding frequency for chicken interfaces was similar to that observed with  $\alpha 9$  as the complementary subunit, it was significantly lower for interfaces showing a rat  $\alpha 10$  complementary subunit (Figure 5E).

Thus, our *in silico* studies focused on the binding site interfaces suggest that the differences of choline responses may be governed by the distinct choline orientation and the differential contribution of binding interfaces containing  $\alpha 10$  as the complementary subunit. While in chicken  $\alpha 9\alpha 10$  receptors a high frequency of choline-binding was observed for all conformations of binding sites, in rat  $\alpha 9\alpha 10$  receptors the frequency of choline-binding was significantly lower at  $\alpha 9/\alpha 10$  and  $\alpha 10/\alpha 10$  sites, suggesting that the lower choline agonism observed in rat  $\alpha 10$  containing receptors (Figures 3, 4) may be related to a reduced capability of the rat  $\alpha 10$  subunit to efficiently operate as the complementary side during agonist binding and receptor gating. Consequently, a reduction in the binding frequency of agonists at specific interfaces might determine differential responses in the context of receptor function.

## The Extracellular Region of the Rat $\alpha 10$ Subunit Underpins Lower Choline Efficacy



The N-terminal and TM2–TM3 extracellular domains of nicotinic receptors bare residues involved both in agonist binding and coupling to pore opening (Karlin, 2002; Bouzat et al., 2004), and most likely contain determinants for agonist efficacy (Gupta et al., 2017; Mukhtasimova and Sine, 2018). Given that choline partial agonism was observed when rat  $\alpha 10$  subunits are present in the heteromeric receptors (Figure 4C) and that, although it binds to all binding site combinations, the frequency of favorable choline-binding was lower at interfaces in which rat  $\alpha 10$  provided the complementary face (Figure 5E), we hypothesized that a receptor in which no binding site contains  $\alpha 10$  components would show strong choline agonism. To test this, we engineered a rat  $\alpha 9$ – $\alpha 10$  ( $\alpha 10_x$ ) chimeric subunit in which the entire N-terminal and TM2–TM3 extracellular regions of the rat  $\alpha 10$  subunit were replaced by the corresponding domains of the rat  $\alpha 9$  subunit (Figure 6A). The chimeric subunit did not form functional homomeric receptors by itself, nor did it do so when co-expressed with the rat  $\alpha 10$  subunit. However, when co-expressed with the rat  $\alpha 9$  subunit, strong ACh responses were recorded for rat  $\alpha 9\alpha 10_x$  receptors (Figure 6B), with  $I_{\max} = 269 \pm 103$  nA ( $n = 5$ ). This contrasts the maximal ACh responses observed for homomeric rat  $\alpha 9$  receptors ( $I_{\max}$  of  $14 \pm 2$  nA,  $n = 4$ ; and see Elgoyhen et al., 2001), indicating that, when co-expressed, rat  $\alpha 9$  and chimeric  $\alpha 10_x$  subunits form heteromeric assemblies. Concentration-response curves for ACh on rat  $\alpha 9\alpha 10_x$  receptors were similar to those of rat  $\alpha 9\alpha 10$  wild-type receptors with an  $EC_{50}$  of  $15.6 \pm 6.5$   $\mu$ M ( $n = 4$ ,  $p = 0.50$ , Kruskal–Wallis test; Figure 6C). Interestingly, responses to choline of the rat  $\alpha 9\alpha 10_x$  chimeric receptor resembled those exhibited by rat  $\alpha 9$  homomeric receptors and differed from those of rat  $\alpha 9\alpha 10$  receptors. Thus, the  $EC_{50}$  for choline on

$\alpha 9\alpha 10_x$  receptors was  $160.2 \pm 7.6$   $\mu$ M ( $n = 5$ ), significantly smaller than that in rat  $\alpha 9\alpha 10$  receptors ( $541 \pm 62$   $\mu$ M,  $n = 10$ ,  $p = 0.007$ , Kruskal–Wallis test) and similar to that observed in homomeric rat  $\alpha 9$  receptors (Figure 6C and Table 1). Likewise, the choline-evoked maximal response of  $74 \pm 1\%$  ( $n = 5$ ) in  $\alpha 9\alpha 10_x$  receptors was higher than that of rat  $\alpha 9\alpha 10$  ( $38 \pm 3\%$ ,  $n = 9$ ,  $p = 0.04$ , Kruskal–Wallis test) but similar to that observed in rat  $\alpha 9$  homomeric receptors ( $87 \pm 6\%$ ,  $n = 4$ ,  $p = 0.27$ , Kruskal–Wallis test; Figure 6C and Table 1). Taken together, the experimental evaluation of ACh and choline agonism in the chimeric receptor indicates that the extracellular region of the rat  $\alpha 10$  subunit bears determinants that reduce the efficacy of choline on the  $\alpha 9\alpha 10$  receptor.

## The $\alpha 10$ Complementary Component Participates in Activation by Choline of Rat $\alpha 9\alpha 10$ nAChRs

In previous work, we showed that rat  $\alpha 10$  subunits do not contribute with complementary faces to the ACh binding site (Boffi et al., 2017). In contrast, in the present study, we have so far shown that the extracellular domain of the rat  $\alpha 10$  subunit is responsible for the decrease in choline agonism in rat  $\alpha 9\alpha 10$  receptors. Moreover, *in silico* docking showed that the frequency of choline-binding in the correct conformation is lower at interfaces where the complementary component is provided by rat  $\alpha 10$  subunits (Figure 5E), suggesting that the lower choline agonism observed in rat  $\alpha 9\alpha 10$  receptors may result from sub-functional  $\alpha 9/\alpha 10$  or  $\alpha 10/\alpha 10$  binding sites. Therefore, to evaluate experimentally choline's requirement for functional binding sites containing  $\alpha 10$  complementary components, we studied responses to choline on rat  $\alpha 9\alpha 10$  heteromeric receptors holding the W55T mutation in the rat  $\alpha 10$  subunits (Figure 7A). W55 is located within loop D of the complementary component of the binding site, which by directly interacting with the agonist is crucial for binding-gating transduction (Olsen et al., 2014). While responses to ACh showed no significant changes in the  $\alpha 9\alpha 10W55T$  receptor compared to wild type  $\alpha 9\alpha 10$  receptors (Boffi et al., 2017; Figures 7A,B and Table 1— $EC_{50}$   $\alpha 9\alpha 10$ :  $17.1 \pm 3.1$   $\mu$ M,  $n = 5$ ;  $EC_{50}$   $\alpha 9\alpha 10W55T$ :  $37.8 \pm 6.2$   $\mu$ M,  $n = 8$ ;  $p = 0.06$ , Kruskal–Wallis test), responses to choline were nearly abolished in mutant receptors. Thus, responses to 10 mM choline were  $7 \pm 2\%$  ( $n = 5$ ) of those elicited by 1 mM ACh (Figure 7B). This indicates that the contribution of the complementary face of the rat  $\alpha 10$  subunit to the agonistic effect of ACh and choline is non-equivalent. Thus, whereas rat  $\alpha 10$  complementary faces are not required for ACh activation of rat  $\alpha 9\alpha 10$  receptors (see also Boffi et al., 2017), intact rat  $\alpha 10$  complementary components are required for choline agonistic effect.

Finally, to evaluate whether choline interacts with the  $\alpha 10/\alpha 9$  intact interfaces in the  $\alpha 9\alpha 10W55T$  receptor, and therefore also requires them to elicit its reduced agonism, we analyzed responses to 10  $\mu$ M ACh in the presence of increasing concentrations of choline for both rat  $\alpha 9\alpha 10$  and  $\alpha 9\alpha 10W55T$  receptors (Figures 7C,D). ACh was added once



a maximal response to choline was observed. The maximal response obtained during the co-application was normalized to the response to 10  $\mu M$  ACh (Figure 7C). At low choline concentrations, that do not trigger channel opening (<100  $\mu M$ ), ACh responses became increasingly smaller as choline concentration increased, both in the  $\alpha 9\alpha 10$  and the  $\alpha 9\alpha 10W55T$  receptors, suggesting that choline is capable of competing with ACh for the available binding sites. However, in the presence of higher choline concentrations (>300  $\mu M$ ), total responses in  $\alpha 9\alpha 10$  receptors increased while they remained unchanged for the mutant receptor (Figure 7D). The V-shaped effect observed in the  $\alpha 9\alpha 10$  receptor, where an  $EC_{50}$  ACh

response is blocked at low concentrations of choline and summation of both agonist responses occurs at higher choline concentrations, is consistent with choline acting as a partial agonist (Zhu, 2005) and suggests that the increase in combined response may be due to choline-binding to the  $\alpha 9/\alpha 10$  and  $\alpha 10/\alpha 10$  sites that are spared by ACh. Conversely, the lack of increase of ACh responses at higher choline concentrations in the  $\alpha 9\alpha 10W55T$  mutant receptor indicates a loss of choline agonism that may result from the unavailability of additional  $\alpha 9/\alpha 10$  and  $\alpha 10/\alpha 10$  sites due to the W55T mutation.

Overall, the differences observed in the responses to ACh and/or choline between  $\alpha 9\alpha 10$  wild type and  $\alpha 9\alpha 10W55T$

mutant receptors indicate that the complementary faces of  $\alpha 10$  subunits are required for the partial agonistic effect of choline on  $\alpha 9\alpha 10$  receptors, therefore suggesting that choline necessitates higher binding site occupancy compared to ACh to elicit channel gating of rat  $\alpha 9\alpha 10$  nAChRs.

## DISCUSSION

The present work shows that the mammalian (rat)  $\alpha 10$  nAChR subunit is responsible for reduced efficacy of choline when assembled into heteromeric  $\alpha 9\alpha 10$  receptors. Thus, whereas choline is a full agonist of rat  $\alpha 9$  homomeric receptors, it is a partial agonist of rat  $\alpha 9\alpha 10$  nAChRs. This is further supported by hybrid receptors, on which choline is a full agonist of rat  $\alpha 9$ -chicken  $\alpha 10$  receptors and the efficacy in chicken heteromeric receptors is reduced when the chicken  $\alpha 10$  subunit is replaced by the rat  $\alpha 10$  subunit in the chicken  $\alpha 9$ -rat  $\alpha 10$  assembly. The reduced agonist efficacy determined by the rat  $\alpha 10$  subunit is probably extended to other compounds that behave as partial agonists, as evidenced in the present work for DMPP. These results add to the differential functional properties between mammalian and non-mammalian vertebrate  $\alpha 9\alpha 10$  nAChRs that have been shaped by the more prevalent occurrence of non-synonymous amino acid substitutions during the evolution of mammalian subunits (Franchini and Elgoyhen, 2006; Elgoyhen and Franchini, 2011; Lipovsek et al., 2012, 2014; Marcovich et al., 2020).

Full and partial agonists evoke distinct structural changes in opening the muscle acetylcholine receptor channel (Mukhtasimova and Sine, 2018). This is further supported by the observation that the  $\alpha E45R$  mutation within the binding-gating transduction domain of this receptor attenuates channel opening by a full agonist, whereas it enhances channel opening by a partial agonist (Mukhtasimova and Sine, 2013). It was, therefore, suggested that, due to differences in size and/or chemical structure, different agonists of the same receptor might bind in different conformations and/or strength to the ligand interaction pocket (Mukhtasimova and Sine, 2018). This resembles our observations on the effect of mutating W55 in the rat  $\alpha 10$  subunit which greatly impairs the response of the  $\alpha 9\alpha 10$  receptor to choline but not to ACh.

This functional non-equivalence between agonists is further supported by docking analysis, which shows that ACh and choline adopt different conformations at the binding site of  $\alpha 9\alpha 10$  receptors. This result fully agrees with previous studies in the muscle nAChR (Bruhova and Auerbach, 2017), for which choline and ACh sit at different orientations at the binding site. In our model, choline had two probable alternate orientations compared to ACh with the least frequent one resembling the one described for the muscle nAChR (Bruhova and Auerbach, 2017). Furthermore, the non-equivalence of the agonist binding sites for ACh and choline is reflected in differential atomic interactions. Thus, similar to ACh, choline can make interactions at the aromatic cage. However, whereas ACh makes an H-bond with the backbone amine group of D119 of the complementary face, choline shows the potential to make an H-bond with the carboxyl group of the same residue (Figures 5B,D). Similar to that

reported for the muscle ACh receptor (Bruhova and Auerbach, 2017), this different orientation leads to the displacement of the quaternary ammonium of choline away from a favorable position in the aromatic cage compared to ACh. This might lead to a weaker interaction with all aromatic rings of the binding site, accounting for the lower apparent affinity of choline compared to ACh for the  $\alpha 9\alpha 10$  receptor. Moreover, due to the particular orientation of choline towards the C-loop when compared to ACh, differential interactions with residues of the complementary face and/or degree of closure of the C-loop required for channel gating (Thompson et al., 2010), might be involved in the reduced choline efficacy.

Our combined *in silico* and experimental observations allow us further insight into the differential responses to ACh and choline of rat  $\alpha 9\alpha 10$  nAChRs. Whereas the complementary face of the  $\alpha 10$  subunit does not play an important role in the activation of the receptor by ACh, it is strictly required for choline responses, as shown by the results of the W55T mutation. ACh adopts a different and more favorable conformation, better placed within the aromatic pocket compared to choline, and would therefore only require occupying two of the five binding sites, sparing binding sites in which the complementary face is provided by the  $\alpha 10$  subunit. However, since choline adopts a less favorable conformation, it probably requires higher binding site occupancy for full efficacy. Differences in agonist efficacy according to available binding sites have been reported for other nAChRs. For example, the  $\alpha 4\beta 2$  nAChR in the  $(\alpha 4)_3(\beta 2)_2$  stoichiometry contains three functional agonist binding sites for ACh (Harpsoe et al., 2011; Mazzaferro et al., 2011), and the engagement of all three agonist sites produces maximal activation. The agonist site at the  $\alpha 4/\alpha 4$  interface is a key determinant of agonist efficacy as occupancy of this site increases agonist efficacy, whereas exclusion from the site leads to partial agonism (Mazzaferro et al., 2014). Another example is provided by the  $\alpha 7$  receptor. Even though maximal activation requires occupancy of three binding sites in the  $\alpha 7$ -5HT<sub>3</sub>A chimera (Rayaes et al., 2009), only one is required in the  $\alpha 7$  nAChR (Andersen et al., 2013). Thus, the relationship between binding site occupancy and maximal response differs between nAChRs. Moreover, and in light of our results, we propose that the degree of occupancy required for maximal responses varies with the type of agonist.

Hair cell  $\alpha 9\alpha 10$  nAChRs are distinct from other nicotinic receptors in that a greater divergence in their coding sequence has translated into differential functional properties across clades (Lipovsek et al., 2012, 2014; Marcovich et al., 2020). Our observations here that choline, the degradation product of ACh, has differential agonistic effects on rodent vs. avian  $\alpha 9\alpha 10$  receptors, suggests different scenarios for the workings of the respective efferent synapses. Recordings on native cholinergic responses recapitulated our observations in recombinant rat and chick  $\alpha 9\alpha 10$  receptors. While choline elicited maximal responses in chicken hair cells, it behaved as a partial agonist of the native nicotinic receptors present in hair cells of mice (Figure 2). These results imply that in chicken efferent synapses to (mostly) short hair cells, the release of ACh from efferent terminals

triggers  $\alpha 9\alpha 10$  receptors that would continue to be activated in response to the choline produced by ACh degradation due to acetylcholinesterase (AChE) activity until it is removed from the synaptic cleft. This would result in longer post-synaptic responses subjected to large variations and poor temporal tuning (Katz and Miledi, 1973). In contrast, in mammalian efferent olivocochlear synapses, the degradation of ACh to choline would limit the time-course and improve the reliability of the cholinergic response. Given that choline is not able to fully activate the rodent  $\alpha 9\alpha 10$  receptor, and in the presence of ACh acts as a competitive antagonist, the termination of  $\alpha 9\alpha 10$  responses would therefore be dictated by the fast kinetics of AChE activity (Hall, 1973). An apical to basal concentration and isoform diversity gradient of AChE has been described in the mouse cochlea (Emmerling and Sobkowicz, 1988). Notably, the high-frequency basal region exhibits higher concentrations of this enzyme and is enriched in isoforms with faster kinetics, underscoring the relevance of fine temporal tuning of efferent modulation for high-frequency sound detection (Emmerling and Sobkowicz, 1988). Additionally, BK channels, that display larger currents with faster kinetics than SK2 channels, participate in efferent synaptic inhibition in higher frequency regions of the cochlea, supporting the notion that accurate control of OHCs membrane potential is required for the amplification and modulation of high frequency hearing (Rohmann et al., 2015). Finally, compared to chicken, the mammalian  $\alpha 9\alpha 10$  receptor shows greater desensitization to ACh and higher calcium permeability (Lipovsek et al., 2012, 2014; Marcovich et al., 2020). In addition, the postsynaptic space delimited by a closely juxtaposed subsynaptic cistern is more restricted in mammals (Fuchs et al., 2014; Im et al., 2014), which may contribute to elicit highly localized  $\alpha 9\alpha 10$ -dependent rises in calcium concentration uncoupled from internal calcium stores (Moglie et al., 2018, 2020). Together with the poorer choline agonism, these multiple functional adaptations may have contributed to “tighter” ACh responses, which may prove fundamental to faithfully reproduce the high frequency activity of efferent medial olivocochlear fibers (Ballester et al., 2011), therefore fine-tuning the modulation of the OHC cochlear amplifier and contributing to the expansion of the mammalian hearing range.

The lower agonistic action of choline on mammalian  $\alpha 9\alpha 10$  receptors is likely due to the accumulation of amino acid changes within the mammalian  $\alpha 10$  subunit (Franchini and Elgoyhen, 2006; Lipovsek et al., 2012) that rendered a subfunctional contribution of  $\alpha 10$  as a complementary component subunit. Our *in silico* and experimental analysis of choline agonism indicate that, for it to trigger a full response, it needs to bind to  $\alpha 9/\alpha 10$  and/or  $\alpha 10/\alpha 10$  sites, therefore requiring sites holding  $\alpha 10$  complementary interfaces. This is in contrast with the agonism by ACh, which only requires binding to  $\alpha 10/\alpha 9$  (or  $\alpha 9/\alpha 9$ ) sites formed by an  $\alpha 10$  (or

$\alpha 9$ ) principal component and  $\alpha 9$  complementary component (Boffi et al., 2017). We hypothesize that amino acid changes within the  $\alpha 10$  subunit that affect agonist binding and/or receptor triggering from the additional binding sites (i.e., those that have an  $\alpha 10$  subunit as a complementary component) would not be deleterious and therefore not under negative selection, as they would not affect the main response to ACh, given that the sensitivity for this agonist is the same in the different species (Lipovsek et al., 2012; Marcovich et al., 2020). In this context, a scenario could be proposed in which strong positive selection pressure for the loss of the agonistic function of choline, a likely functional requirement for the fine-tuned high-frequency efferent olivocochlear activity, may have been the driver for the accumulation of coding sequence changes within the extracellular domain of mammalian  $\alpha 10$  subunits (Franchini and Elgoyhen, 2006). This then resulted in the loss of choline acting as a full agonist for mammalian  $\alpha 9\alpha 10$  receptors, without affecting the triggering of ACh responses.

## DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

## ETHICS STATEMENT

The animal study was reviewed and approved by Instituto de Investigaciones en Ingeniería Genética y Biología Molecular “Dr. Héctor N. Torres” (INGEBI) Institutional Animal Care and Use Committee.

## AUTHOR CONTRIBUTIONS

MM, IM, JC, CB, ML, and ABE designed the research. MM, IM, JC, AC, and SG performed the research. PP provided reagents. MM, IM, CB, ML, and ABE wrote the article. ABE raised funding. All authors contributed to the article and approved the submitted version.

## FUNDING

This work was supported by Agencia Nacional de Promoción Científicas y Técnicas, Argentina, the Scientific Grand Prize of the Fondation Pour l’Audition, and NIH grant R01 DC001508 (Paul Fuchs PI and ABE co-PI) to ABE.

## ACKNOWLEDGMENTS

We thank Paul A. Fuchs for assistance in the performance of chicken hair cell recordings.

## REFERENCES

Albuquerque, E. X., Pereira, E. F., Braga, M. F., and Alkondon, M. (1998). Contribution of nicotinic receptors to the function of synapses in the central nervous system: the action of choline as a selective agonist of

$\alpha 7$  receptors. *J. Physiol. Paris* 92, 309–316. doi: 10.1016/s0928-4257(98)80039-9

Andersen, N., Corradi, J., Sine, S. M., and Bouzat, C. (2013). Stoichiometry for activation of neuronal  $\alpha 7$  nicotinic receptors. *Proc. Natl. Acad. Sci. U S A* 110, 20819–20824. doi: 10.1073/pnas.1315775110



- Arnold, K., Bordoli, L., Kopp, J., and Schwede, T. (2006). The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. *Bioinformatics* 22, 195–201. doi: 10.1093/bioinformatics/bti770
- Ballestero, J. A., Plazas, P. V., Kracun, S., Gomez-Casati, M. E., Taranda, J., Rothlin, C. V., et al. (2005). Effects of quinine, quinidine and chloroquine on  $\alpha 9\alpha 10$  nicotinic cholinergic receptors. *Mol. Pharmacol.* 68, 822–829. doi: 10.1124/mol.105.014431
- Ballestero, J., Zorrilla de San Martin, J., Goutman, J., Elgoyhen, A. B., Fuchs, P. A., and Katz, E. (2011). Short-term synaptic plasticity regulates the level of olivocochlear inhibition to auditory hair cells. *J. Neurosci.* 31, 14763–14774. doi: 10.1523/JNEUROSCI.6788-10.2011
- Boffi, J. C., Marcovich, I., Gill-Thind, J. K., Corradi, J., Collins, T., Lipovsek, M. M., et al. (2017). Differential contribution of subunit interfaces to  $\alpha 9\alpha 10$  nicotinic acetylcholine receptor function. *Mol. Pharmacol.* 91, 250–262. doi: 10.1124/mol.116.107482
- Bordoli, L., Kiefer, F., Arnold, K., Benkert, P., Battey, J., and Schwede, T. (2009). Protein structure homology modeling using SWISS-MODEL workspace. *Nat. Protoc.* 4, 1–13. doi: 10.1038/nprot.2008.197
- Bouzat, C., Gumilar, F., Spitzmaul, G., Wang, H. L., Rayes, D., Hansen, S. B., et al. (2004). Coupling of agonist binding to channel gating in an ACh-binding protein linked to an ion channel. *Nature* 430, 896–900. doi: 10.1038/nature02753
- Bruhova, I., and Auerbach, A. (2017). Molecular recognition at cholinergic synapses: acetylcholine versus choline. *J. Physiol.* 595, 1253–1261. doi: 10.1113/JP273291
- Dougherty, D. A. (2007). Cation- $\pi$  interactions involving aromatic amino acids. *J. Nutr.* 137, 1504S–1508S. doi: 10.1093/jn/137.6.1504S
- Dulon, D., and Lenoir, M. (1996). Cholinergic responses in developing outer hair cells of the rat cochlea. *Eur. J. Neurosci.* 8, 1945–1952. doi: 10.1111/j.1460-9568.1996.tb01338.x
- Elgoyhen, A. B., and Franchini, L. F. (2011). Prestin and the cholinergic receptor of hair cells: positively-selected proteins in mammals. *Hear. Res.* 273, 100–108. doi: 10.1016/j.heares.2009.12.028
- Elgoyhen, A. B., Johnson, D. S., Boulter, J., Vetter, D. E., and Heinemann, S. (1994).  $\alpha 9$ : an acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. *Cell* 79, 705–715. doi: 10.1016/0092-8674(94)90555-x
- Elgoyhen, A. B., and Katz, E. (2012). The efferent medial olivocochlear-hair cell synapse. *J. Physiol. Paris* 106, 47–56. doi: 10.1016/j.jphysparis.2011.06.001
- Elgoyhen, A. B., Katz, E., and Fuchs, P. A. (2009). The nicotinic receptor of cochlear hair cells: a possible pharmacotherapeutic target? *Biochem. Pharmacol.* 78, 712–719. doi: 10.1016/j.bcp.2009.05.023
- Elgoyhen, A. B., Vetter, D., Katz, E., Rothlin, C., Heinemann, S., and Boulter, J. (2001).  $\alpha 10$ : a determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells. *Proc. Natl. Acad. Sci. U S A* 98, 3501–3506. doi: 10.1073/pnas.051622798
- Emmerling, M. R., and Sobkowitz, H. M. (1988). Differentiation and distribution of acetylcholinesterase molecular forms in the mouse cochlea. *Hear. Res.* 32, 137–145. doi: 10.1016/0378-5955(88)90086-x
- Franchini, L. F., and Elgoyhen, A. B. (2006). Adaptive evolution in mammalian proteins involved in cochlear outer hair cell electromotility. *Mol. Phylogenet. Evol.* 41, 622–635. doi: 10.1016/j.ympev.2006.05.042
- Fuchs, P. A., Lehar, M., and Hiel, H. (2014). Ultrastructure of cisternal synapses on outer hair cells of the mouse cochlea. *J. Comp. Neurol.* 522, 717–729. doi: 10.1002/cne.23478
- Fuchs, P. A., and Murrow, B. W. (1992). A novel cholinergic receptor mediates inhibition of chick cochlear hair cells. *Proc. R. Soc. Lond. B* 248, 35–40. doi: 10.1098/rspb.1992.0039
- Gomez-Casati, M. E., Fuchs, P. A., Elgoyhen, A. B., and Katz, E. (2005). Biophysical and pharmacological characterization of nicotinic cholinergic receptors in cochlear inner hair cells. *J. Physiol.* 566, 103–118. doi: 10.1113/jphysiol.2005.087155
- Goutman, J. D., Elgoyhen, A. B., and Gomez-Casati, M. E. (2015). Cochlear hair cells: the sound-sensing machines. *FEBS Lett.* 589, 3354–3361. doi: 10.1016/j.febslet.2015.08.030
- Guex, N., and Peitsch, M. C. (1997). SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. *Electrophoresis* 18, 2714–2723. doi: 10.1002/elps.1150181505
- Gupta, S., Chakraborty, S., Vij, R., and Auerbach, A. (2017). A mechanism for acetylcholine receptor gating based on structure, coupling, phi and flip. *J. Gen. Physiol.* 149, 85–103. doi: 10.1085/jgp.201611673
- Hall, Z. W. (1973). Multiple forms of acetylcholinesterase and their distribution in endplate and non-endplate regions of rat diaphragm muscle. *J. Neurobiol.* 4, 343–361. doi: 10.1002/neu.480040404
- Harpsoe, K., Ahring, P. K., Christensen, J. K., Jensen, M. L., Peters, D., and Balle, T. (2011). Unraveling the high- and low-sensitivity agonist responses of nicotinic acetylcholine receptors. *J. Neurosci.* 31, 10759–10766. doi: 10.1523/JNEUROSCI.1509-11.2011
- Hernando, G., Bergé, I., Rayes, D., and Bouzat, C. (2012). Contribution of subunits to *Caenorhabditis elegans* levamisole-sensitive nicotinic receptor function. *Mol. Pharmacol.* 82, 550–560. doi: 10.1124/mol.112.079962
- Horton, R. M., Hunt, H. D., Ho, S. N., Pullen, J. K., and Pease, L. R. (1989). Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. *Gene* 77, 61–68. doi: 10.1016/0378-1119(89)90359-4
- Humphrey, W., Dalke, A., and Schulten, K. (1996). VMD: visual molecular dynamics. *J. Mol. Graph.* 14, 33–38, 27–38. doi: 10.1016/0263-7855(96)00018-5
- Im, G. J., Moskowitz, H. S., Lehar, M., Hiel, H., and Fuchs, P. A. (2014). Synaptic calcium regulation in hair cells of the chicken basilar papilla. *J. Neurosci.* 34, 16688–16697. doi: 10.1523/JNEUROSCI.2615-14.2014
- Karlin, A. (2002). Ion channel structure: emerging structure of the nicotinic acetylcholine receptors. *Nat. Rev. Neurosci.* 3, 102–114. doi: 10.1038/nrn731
- Katz, E., and Elgoyhen, A. B. (2014). Short-term plasticity and modulation of synaptic transmission at mammalian inhibitory cholinergic olivocochlear synapses. *Front. Syst. Neurosci.* 8:224. doi: 10.3389/fnsys.2014.00224
- Katz, E., Elgoyhen, A. B., Gomez-Casati, M. E., Knipper, M., Vetter, D. E., Fuchs, P. A., et al. (2004). Developmental regulation of nicotinic synapses on cochlear inner hair cells. *J. Neurosci.* 24, 7814–7820. doi: 10.1523/JNEUROSCI.2102-04.2004
- Katz, B., and Miledi, R. (1973). The binding of acetylcholine to receptors and its removal from the synaptic cleft. *J. Physiol.* 231, 549–574. doi: 10.1113/jphysiol.1973.sp010248
- Lester, H. A., Dibas, M. I., Dahan, D. S., Leite, J. F., and Dougherty, D. A. (2004). Cys-loop receptors: new twists and turns. *Trends Neurosci.* 27, 329–336. doi: 10.1016/j.tins.2004.04.002
- Lipovsek, M., Fierro, A., Perez, E. G., Boffi, J. C., Millar, N. S., Fuchs, P. A., et al. (2014). Tracking the molecular evolution of calcium permeability in a nicotinic acetylcholine receptor. *Mol. Biol. Evol.* 31, 3250–3265. doi: 10.1093/molbev/msu258
- Lipovsek, M., Im, G. J., Franchini, L. F., Pisciotto, F., Katz, E., Fuchs, P. A., et al. (2012). Phylogenetic differences in calcium permeability of the auditory hair cell cholinergic nicotinic receptor. *Proc. Natl. Acad. Sci. U S A* 109, 4308–4313. doi: 10.1073/pnas.1115488109
- Manley, G. A. (2000). Cochlear mechanisms from a phylogenetic viewpoint. *Proc. Natl. Acad. Sci. U S A* 97, 11736–11743. doi: 10.1073/pnas.97.22.11736
- Marcovich, I., Moglie, M. J., Carpaneto Freixas, A. E., Trigila, A. P., Franchini, L. F., Plazas, P. V., et al. (2020). Distinct evolutionary trajectories of neuronal and hair cell nicotinic acetylcholine receptors. *Mol. Biol. Evol.* 37, 1070–1089. doi: 10.1093/molbev/msz290
- Mazzaferro, S., Benallegue, N., Carbone, A., Gasparri, F., Vijayan, R., Biggin, P. C., et al. (2011). Additional acetylcholine (ACh) binding site at  $\alpha 4/\alpha 4$  interface of  $(\alpha 4\beta 2)_2\alpha 4$  nicotinic receptor influences agonist sensitivity. *J. Biol. Chem.* 286, 31043–31054. doi: 10.1074/jbc.M111.262014
- Mazzaferro, S., Gasparri, F., New, K., Alcaino, C., Faundez, M., Iturriaga Vasquez, P., et al. (2014). Non-equivalent ligand selectivity of agonist sites in  $(\alpha 4\beta 2)_2\alpha 4$  nicotinic acetylcholine receptors: a key determinant of agonist efficacy. *J. Biol. Chem.* 289, 21795–21806. doi: 10.1074/jbc.M114.555136
- Miledi, R., and Parker, I. (1984). Chloride current induced by injection of calcium into *Xenopus oocytes*. *J. Physiol.* 357, 173–183. doi: 10.1113/jphysiol.1984.sp015495
- Moglie, M. J., Fuchs, P. A., Elgoyhen, A. B., and Goutman, J. D. (2018). Compartmentalization of antagonistic  $Ca^{2+}$  signals in developing cochlear

- hair cells. *Proc. Natl. Acad. Sci. U S A* 115, E2095–E2104. doi: 10.1073/pnas.1719077115
- Moglie, M. J., Wengier, D. L., Elgoyhen, A. B., and Goutman, J. D. (2020). Synaptic contributions to cochlear outer hair cell  $\text{Ca}^{2+}$  homeostasis. *bioRxiv* [Preprint] doi: 10.1101/2020.08.02.233205
- Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., et al. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J. Comput. Chem.* 30, 2785–2791. doi: 10.1002/jcc.21256
- Mukhtasimova, N., and Sine, S. M. (2013). Nicotinic receptor transduction zone: invariant arginine couples to multiple electron-rich residues. *Biophys. J.* 104, 355–367. doi: 10.1016/j.bpj.2012.12.013
- Mukhtasimova, N., and Sine, S. M. (2018). Full and partial agonists evoke distinct structural changes in opening the muscle acetylcholine receptor channel. *J. Gen. Physiol.* 150, 713–729. doi: 10.1085/jgp.201711881
- Olsen, J. A., Balle, T., Gajhede, M., Ahring, P. K., and Kastrup, J. S. (2014). Molecular recognition of the neurotransmitter acetylcholine by an acetylcholine binding protein reveals determinants of binding to nicotinic acetylcholine receptors. *PLoS One* 9:e91232. doi: 10.1371/journal.pone.0091232
- Pujol, R., Lavigne-Revillard, M., and Lenoir, M. (1998). “Development of sensory and neural structures in the mammalian cochlea,” in *Development of the Auditory System*, eds E. Rubel, A. Popper, and R. Fay (New York, NY: Springer), 146–192.
- Rayes, D., De Rosa, M. J., Sine, S. M., and Bouzat, C. (2009). Number and locations of agonist binding sites required to activate homomeric Cys-loop receptors. *J. Neurosci.* 29, 6022–6032. doi: 10.1523/JNEUROSCI.0627-09.2009
- Rohmann, K. N., Wersinger, E., Braude, J. P., Pyott, S. J., and Fuchs, P. A. (2015). Activation of BK and SK channels by efferent synapses on outer hair cells in high-frequency regions of the rodent cochlea. *J. Neurosci.* 35, 1821–1830. doi: 10.1523/JNEUROSCI.2790-14.2015
- Rothlin, C. V., Lioudyno, M. I., Silbering, A. F., Plazas, P. V., Casati, M. E., Katz, E., et al. (2003). Direct interaction of serotonin type 3 receptor ligands with recombinant and native  $\alpha 9\alpha 10$ -containing nicotinic cholinergic receptors. *Mol. Pharmacol.* 63, 1067–1074. doi: 10.1124/mol.63.5.1067
- Rothlin, C., Verbitsky, M., Katz, E., and Elgoyhen, A. (1999). The  $\alpha 9$  nicotinic acetylcholine receptor shares pharmacological properties with type A  $\alpha$ -aminobutyric acid, glycine and type 3 serotonin receptors. *Mol. Pharmacol.* 55, 248–254. doi: 10.1124/mol.55.2.248
- Russell, R. B., and Barton, G. J. (1992). Multiple protein sequence alignment from tertiary structure comparison: assignment of global and residue confidence levels. *Proteins* 14, 309–323. doi: 10.1002/prot.340140216
- Schwede, T., Kopp, J., Guex, N., and Peitsch, M. C. (2003). SWISS-MODEL: an automated protein homology-modeling server. *Nucleic. Acids Res.* 31, 3381–3385. doi: 10.1093/nar/gkg520
- Sgard, F., Charpentier, E., Bertrand, S., Walker, N., Caput, D., Graham, D., et al. (2002). A novel human nicotinic receptor subunit,  $\alpha 10$ , that confers functionality to the  $\alpha 9$ -subunit. *Mol. Pharmacol.* 61, 150–159. doi: 10.1124/mol.61.1.150
- Simmons, D. D. (2002). Development of the inner ear efferent system across vertebrate species. *J. Neurobiol.* 53, 228–250. doi: 10.1002/neu.10130
- Thompson, A. J., Lester, H. A., and Lummis, S. C. (2010). The structural basis of function in Cys-loop receptors. *Q. Rev. Biophys.* 43, 449–499. doi: 10.1017/S0033583510000168
- Tomaselli, G. F., McLaughlin, J. T., Jurman, M. E., Hawrot, E., and Yellen, G. (1991). Mutations affecting agonist sensitivity of the nicotinic acetylcholine receptor. *Biophys. J.* 60, 721–727. doi: 10.1016/S0006-3495(91)82102-6
- Verbitsky, M., Rothlin, C., Katz, E., and Elgoyhen, A. B. (2000). Mixed nicotinic-muscarinic properties of the  $\alpha 9$  nicotinic cholinergic receptor. *Neuropharmacology* 39, 2515–2524. doi: 10.1016/s0028-3908(00)00124-6
- Wehrwein, E. A., Orer, H. S., and Barman, S. M. (2016). Overview of the anatomy, physiology and pharmacology of the autonomic nervous system. *Comp. Physiol.* 6, 1239–1278. doi: 10.1002/cphy.c150037
- Zhu, B. T. (2005). Mechanistic explanation for the unique pharmacologic properties of receptor partial agonists. *Biomed. Pharmacother.* 59, 76–89. doi: 10.1016/j.biopha.2005.01.010
- Zouridakis, M., Giastas, P., Zarkadas, E., Chroni-Tzartou, D., Bregestovski, P., and Tzartos, S. J. (2014). Crystal structures of free and antagonist-bound states of human  $\alpha 9$  nicotinic receptor extracellular domain. *Nat. Struct. Mol. Biol.* 21, 976–980. doi: 10.1038/nsmb.2900

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Moglie, Marcovich, Corradi, Carpaneto Freixas, Gallino, Plazas, Bouzat, Lipovsek and Elgoyhen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.